Clinical Trials
22
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (20 trials with phase data)• Click on a phase to view related trials
Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients
- Conditions
- Mucopolysaccharidosis Type 1
- Interventions
- Biological: LaronidaseDrug: AntihistamineDrug: Antipyretic
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 12
- Registration Number
- NCT06406153
- Locations
- 🇮🇷
Clinical Research Development Unit of Akbar Hospital, Faculty of Medicine, Mashhad, Iran, Islamic Republic of
🇮🇷Growth and Development Research Center, Childrens Medical Center, Tehran, Iran, Islamic Republic of
🇮🇷Loghman Hospital, Tehran, Iran, Islamic Republic of
Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
- Conditions
- Allergic AsthmaUncontrolled Moderate to Severe
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 256
- Registration Number
- NCT05813470
- Locations
- 🇮🇷
Golestan Hospital, Ahvaz, Iran, Islamic Republic of
🇮🇷Imam Khomeini, Ahvaz, Iran, Islamic Republic of
🇮🇷Khorshid Hospital, Isfahan, Iran, Islamic Republic of
Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration
- Conditions
- Age-Related Macular DegenerationNeovascular Age-related Macular Degeneration
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 168
- Registration Number
- NCT05587062
- Locations
- 🇮🇷
Farabi Hospital, Tehran, Iran, Islamic Republic of
Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine
- Conditions
- COVID-19
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2023-08-31
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 43
- Registration Number
- NCT05285384
- Locations
- 🇮🇷
Shaheed Labbafinezhad Hospital, Tehran, Iran, Islamic Republic of
Efficacy and Safety of Peginterferon Beta-1a (CinnaGen) in Participants With Relapsing Remitting Multiple Sclerosis
- Conditions
- Relapsing Remitting Multiple Sclerosis (RRMS)
- Interventions
- Drug: Interferon Beta-1A Prefilled Syringe
- First Posted Date
- 2022-02-16
- Last Posted Date
- 2022-10-18
- Lead Sponsor
- Cinnagen
- Target Recruit Count
- 168
- Registration Number
- NCT05242133
- Locations
- 🇮🇷
Sina Hospital, Tehran, Iran, Islamic Republic of
- Prev
- 1
- 2
- 3
- 4
- Next